Heather M. Schneider is a partner in the Intellectual Property Department. Heather’s practice focuses on patent litigation, as well as antitrust issues involving intellectual property. Her litigation experience encompasses an array of technologies, including pharmaceuticals and biologic products, computer software, medical devices, and chemical products. Her practice also includes client counseling on patent issues, as well as intellectual property issues associated with transactional work including licensing, mergers, and bankruptcy.
In the pharmaceutical field, Heather has played a significant role in litigations and appeals for major life sciences companies involving drug products including: oxycodone HCI (OxyContin), erythropoietin (Epogen), dexmedetomidine (Precedex), rotigotine (Neupro), fingolimod (Gilenya), paricalcitol (Zemplar), argatroban (Argatroban Injection), and amlodipine besylate (Norvasc). In the computer field, Heather appeared before the U.S. and Canadian courts in the Nortel bankruptcy litigation involving the allocation of proceeds from the sale of Nortel’s $4.5 billion portfolio of telecommunications patents. She has also worked on patent litigation and antitrust issues involving standard-essential patents in the chemical industry.